Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Appointed director
NEUROCRINE BIOSCIENCES INC (NBIX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Other Events  Interactive Data
10/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Neurocrine Biosciences Announces Phase 3 Pediatric Study Results of Crinecerfont in Children and Adolescents for the Treatment of Congenital Adrenal Hyperplasia Met Primary and Key Secondary Endpoints"
10/02/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/22/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/01/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 8-K Quarterly results
07/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BYLAW AMENDMENT"
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/03/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Quarterly results
05/01/2023 144 Form 144 - Report of proposed sale of securities:
04/24/2023 144 Form 144 - Report of proposed sale of securities:
04/19/2023 144 Form 144 - Report of proposed sale of securities:
04/18/2023 144 Form 144 - Report of proposed sale of securities:
04/06/2023 ARS Form ARS - Annual Report to Security Holders:
04/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/24/2023 SC 13D/A NEUROCRINE BIOSCIENCES INC reports a 19.9% stake in VOYAGER THERAPEUTICS, INC.
02/10/2023 8-K Quarterly results
02/09/2023 10-K Annual Report for the period ended December 31, 2022
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 9.7% stake in Neurocrine Biosciences Inc.
02/09/2023 SC 13G/A JANUS HENDERSON GROUP PLC reports a 2.5% stake in NEUROCRINE BIOSCIENCES, INC.
02/06/2023 8-K Quarterly results
Docs: "Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy